Compare BioNTech SE - ADR (BNTX) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Synopsys, Inc. — how do they compare? BioNTech SE - ADR trades at $92.8 (market cap $23.31B), while Synopsys, Inc. trades at $410.7 (market cap $78.68B). The key difference: Synopsys, Inc. is far larger — about 3.4× BioNTech SE - ADR's market cap. Which is the better fit depends on your goals.
| BNTX | SNPS | |
|---|---|---|
Market Cap | $23.31B | $78.68B |
Sector | Health | Technology |
52-Week High | $119.34 | $625.80 |
52-Week Low | $83.89 | $372.33 |
Enterprise Value | $6.60B | $87.04B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
